hotspot -WSS

hotspot

author：fashion 2025-08-08 05:32:50 - browse：38892

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

focus

WSS

Biotech startup Celsius cuts 75% of staff ahead of first trial start

How to ethically and practically extend health care to all

Flint parents haunted by uncertainty, fears of lead poisoning

How to ethically and practically extend health care to all

Lupron, used to halt puberty in children, may cause lasting health problems

Flint parents haunted by uncertainty, fears of lead poisoning

hotspot

hotspot

knowledge

Peter Hotez and the public health issue of online harassment

2 officers injured in shooting in Orlando, police say

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Medicare slashes safety net hospital payments by nearly $1 billion

Sports medicine is finally prioritizing gender equality

Flint parents haunted by uncertainty, fears of lead poisoning

State Dept. review finds Biden bears some blame for Afghanistan failures

STAT wants to know your pick for a great summer read or listen

After affirmative action ruling, medical educators look to 'holistic review'

A letter from the executive editor: The 2023 STATUS List

hotspot

FDA approves Sage Therapeutics’ rapid

Canadians with cystic fibrosis outlive Americans by a decade

Undocumented workers face uncertainty as immigration law takes effect in Florida

Study links childhood stress with decline in older age

STAT wants to know your pick for a great summer read or listen

Crowdfunding for unproven stem cell procedures spreads misinformation

Wikipedia

focus

focus

focus